Rationale primary prevention study low-dose aspirin coronary cerebrovascular disease elderly benefits prophylactic aspirin therapy cardiovascular cerebrovascular disease asymptomatic individuals unclear rationale double-blind placebo-controlled clinical trial low-dose aspirin mg prevents cardiovascular cerebrovascular morbidity mortality persons years evidence pre-existing cardiovascular cerebrovascular disease Sample size calculations subjects follow-up period order reduction overall cardiovascular mortality level power large-scale community-based clinical trial Australia age group PACE prevention low-dose aspirin cardiovascular disease elderly pilot study recruitment strategies methods disease end-points 